This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): recombinant immunotoxin BL22, GCR-3888
Description: CAT-3888 is an immunotoxin fusion protein consisting of an anti-CD22 disulfide-linked Fv antibody fragment and the exotoxin PE38 from Pseudomonas. CAT-3888 is designed to bind and kill cancer cells that express CD22 on their surface.
Deal Structure: Cambridge Antibody Technology (CAT) announced in November 2005 the acquisition of GCR-3888 from Genencor. The consideration for the acquisition is up to $16 million, of which $14 million will be paid by CAT on closing. Simultaneously, Genencor will subscribe $14 million for 1,170,277 new CAT ordinary shares (representing 2.27 percent of CAT's existing issued share capital).
In June 2006, CAT became a subsidiary of AstraZeneca.
Partners: Danisco A/S
Additional information available to subscribers only: